Prodrug Strength in FDA Labeling: Active Moiety Versus the Prodrug
For a prodrug program, the strength stated on the label is not a cosmetic choice — it follows from regulatory definitions and shapes how dosing, bioequivalence, and comparative claims are read by reviewers and prescribers. Anticipating which convention FDA will apply, rather than discovering it late, can be the difference between a clean submission and one that stalls on a labeling question.
This analysis lays out the framework FDA uses to decide whether a product's strength is expressed in active-moiety equivalents or as the prodrug itself, then works through the approved precedents that fall on each side. The aim is to help regulatory and formulation teams predict where a given molecule is likely to land.
Want to ask Rhizome your own regulatory questions? Try it for free.
Expressing prodrug strength on FDA labeling: the active moiety versus the prodrug
One of the recurring formulation-labeling questions in a prodrug program is deceptively simple: what number goes on the "strength" line? Do you declare the mass of the prodrug you actually put in the vial or tablet, or the amount of active moiety it liberates in vivo? FDA has not answered that question with a single blanket rule for prodrugs. Instead, the outcome falls out of a small set of governing definitions and conventions, and the approved precedents split cleanly into two camps: products whose strength is stated in active-moiety equivalents, and products whose strength is stated as the prodrug itself. Understanding why a given product landed in one camp or the other is what lets a sponsor predict where its own molecule will land.
The governing framework: active moiety, 21 CFR 201.10, and the salt policy
The pivotal concept is the regulatory definition of active moiety. FDA defines it as "the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt … or other noncovalent derivative … responsible for the physiological or pharmacological action of the drug substance" 4041. Two features of that wording drive everything downstream. First, esters and salts are explicitly stripped out, so the active moiety of an ester or salt is the parent molecule. Second, only noncovalent derivatives beyond esters are excluded, which means a covalent, non-ester conjugate (an amide, for example) is not stripped out and the conjugate itself is the active moiety.
For salts, FDA's expectations on how strength is presented are set out in the agency's guidance on naming drug products that contain salt drug substances, which implements the USP Salt Policy (USP General Chapter <1121>, Nomenclature) and cross-references 21 CFR 201.10 8586. The guidance recommends that both the product name and the labeled strength generally be based on the active moiety rather than the salt 8486. When that approach is used, the label carries three elements working together: the active-moiety-based strength, the full name and full strength of the specific salt form elsewhere on the labeling, and an equivalency statement tying the two together 8689. The guidance's own worked examples show the pattern, for instance "New Drug … 10 mg" with "(equivalent to 10.5 mg New Drug Hydrochloride USP)," and, for an ester, "New Drug … 10 mg" with "(equivalent to 8.72 mg New Drug)" for a palmitate salt 88102.
That palmitate example is the bridge to prodrugs. Because the active-moiety definition excludes esters, an ester prodrug (a phosphate, succinate, or similar) is treated on the same logic as a salt: the active moiety is the parent drug, and the strength convention pushes toward parent-based expression with an equivalency statement. A covalent non-ester prodrug does not get that treatment, which is the fault line running through the precedents below.
Precedents that state strength in active-moiety terms
Fosphenytoin (Cerebyx) is the cleanest and most consequential example. Its strength and dosing are expressed entirely in phenytoin sodium equivalents (PE), never in fosphenytoin milligrams. Labeling states that Cerebyx should "always [be] prescribed and dispensed in phenytoin sodium equivalent (PE)" and that "fosphenytoin concentrations, doses, and IV administration rates are always expressed as phenytoin sodium equivalents (PE)" 474849505254565758. The convention is anchored to the molar relationship: 1.5 mg of fosphenytoin sodium equals 1 mg of phenytoin sodium equals 1 mg PE, because fosphenytoin is a prodrug that is rapidly and completely converted to phenytoin, with 1 mmol of fosphenytoin producing 1 mmol of phenytoin 46515254. FDA's rationale was safety and dose comparability: stating strength in PE lets clinicians move between fosphenytoin and phenytoin without performing molecular-weight adjustments and prevents dosing errors arising from the two molecules' different masses 50515254.
Oseltamivir phosphate (Tamiflu) follows the salt convention. The dosage form contains the phosphate salt, but the labeled milligram strength is the oseltamivir free-base equivalent: capsules are described as 30 mg, 45 mg, and 75 mg free-base equivalents of the phosphate salt, and the oral suspension is expressed in base terms as well 118121122124130119120125129. Labeling separately notes that oseltamivir phosphate is the prodrug and oseltamivir carboxylate is the active species 117.
Isavuconazonium sulfate (Cresemba) expresses strength as the salt but pairs every strength with an explicit isavuconazole equivalency: 74.5 mg isavuconazonium sulfate equals 40 mg isavuconazole, 186 mg equals 100 mg (capsule), and 372 mg equals 200 mg (for injection) 727477798083. Because isavuconazole is the active moiety and the water-soluble isavuconazonium is cleaved in vivo, dosing throughout the label is driven by the isavuconazole number.
Ester prodrugs of already-marketed parents show the same behavior even where the word "prodrug" is not the label's headline. Clindamycin phosphate strength is stated as "clindamycin phosphate equivalent to 300, 600 and 900 mg of clindamycin," with labeling noting the phosphate is biologically inactive until converted to clindamycin 154155156158159161163164167168. Methylprednisolone sodium succinate (Solu-Medrol) is labeled as "methylprednisolone sodium succinate equivalent to 40 mg [125 mg, 500 mg, 1 gram, 2 grams] methylprednisolone," and is expressly identified as "the sodium succinate ester of methylprednisolone" 132133134135136137141. In both cases the parent drug already existed on the market, so expressing the ester's strength in parent-equivalent terms preserves therapeutic continuity and dosing familiarity.
Precedents that state strength as the prodrug itself
Lisdexamfetamine dimesylate (Vyvanse) is the instructive counterexample. Its strength is stated in milligrams of lisdexamfetamine dimesylate, and the only equivalency the label gives is to lisdexamfetamine (the free base), not to the pharmacologically active dextroamphetamine: 10, 20, 30, 40, 50, 60, and 70 mg of the dimesylate salt are stated as equivalent to 5.8, 11.6, 17.3, 23.1, 28.9, 34.7, and 40.5 mg of lisdexamfetamine 242829. The label describes lisdexamfetamine as a prodrug of dextroamphetamine but does not re-express the strengths in dextroamphetamine terms 242630. The chemistry explains the choice: lisdexamfetamine is a covalent amide conjugate of L-lysine and dextroamphetamine, not an ester or salt of dextroamphetamine, so under the active-moiety definition the amide conjugate itself is the active moiety. The salt (dimesylate) is stripped out, hence the equivalency to lisdexamfetamine free base, but the active-moiety logic stops there and never reaches dextroamphetamine.
Tenofovir alafenamide (Vemlidy) expresses strength as the prodrug: "25 mg of tenofovir alafenamide (equivalent to 28 mg of tenofovir alafenamide fumarate)," with the equivalency running only to the fumarate salt, not to tenofovir 6568. The review record confirms that TAF is a prodrug converted in vivo to the active tenofovir diphosphate and contrasts it with tenofovir disoproxil fumarate, noting TAF delivers higher intracellular active metabolite with roughly 90% lower circulating tenofovir 666769. This is a useful illustration of a divergence sponsors should anticipate: tenofovir is the shared active moiety for exclusivity purposes across TAF and TDF, yet the label's strength line is built on the prodrug, not the active moiety.
Tedizolid phosphate (Sivextro) is labeled purely as the phosphate prodrug, for example "Tedizolid phosphate tablets, 200 mg," and the injection is formulated to deliver 200 mg of tedizolid phosphate after reconstitution 14. The label identifies it as "a phosphate prodrug" and explains that pharmacokinetics are characterized in terms of tedizolid because prodrug exposure is negligible, but it provides no "equivalent to X mg tedizolid" statement 341720.
Gabapentin enacarbil (Horizant) likewise carries strength as the prodrug: each extended-release tablet contains 300 mg or 600 mg of gabapentin enacarbil, with no gabapentin-equivalent restatement in the approved strength line 175176177178. A gabapentin equivalence (600 mg gabapentin enacarbil equal to 312 mg gabapentin) appears in the review record but was not carried into the labeled strength 174. Valganciclovir (Valcyte) is described and labeled as valganciclovir hydrochloride, a valyl-ester prodrug rapidly hydrolyzed to ganciclovir; the strength is expressed on the salt/prodrug rather than as a ganciclovir equivalent 187188189.
What determines which convention applies
Reading across the precedents, a few practical determinants emerge for regulatory teams planning a prodrug label.
The chemistry of the linkage is the first gate. Where the prodrug is an ester or a salt of a defined parent active moiety, the salt-naming/USP framework points toward parent-equivalent strength plus an equivalency statement (clindamycin phosphate, methylprednisolone succinate, and the phosphate-ester fosphenytoin) 8689132154. Where the prodrug is a covalent non-ester conjugate, the conjugate is itself the active moiety and strength is naturally stated on the prodrug, with any salt equivalency reaching only the free base (lisdexamfetamine) 2428.
The second determinant is whether the active moiety is an established, separately marketed drug. When it is, active-moiety expression buys dose comparability and substitution safety, which is exactly the rationale FDA articulated for the phenytoin-equivalent (PE) convention and the reason legacy steroid esters and clindamycin phosphate are dosed in parent terms 505254. When the prodrug is a new molecular entity with no clinically interchangeable marketed parent, the strength is generally carried on the prodrug (tenofovir alafenamide, tedizolid phosphate, gabapentin enacarbil) 651175.
Finally, even where strength is expressed on the prodrug, FDA's consistent expectation is that the relationship to the active moiety be made transparent somewhere in the labeling, whether through a formal equivalency statement (isavuconazonium to isavuconazole, oseltamivir base equivalents) or through clinical pharmacology text describing the conversion and the active species 7411717. The safest reading of the precedents is that the strength line itself is negotiable and product-specific, but a clear, quantitative link between what is in the dosage form and what acts in the patient is not.